High-throughput Discovery of Chemical Probes for HIV-1 Nef Function
High-throughput Discovery of Chemical Probes for HIV-1 Nef Function
批准号:
9220841
负责人:
Thomas E. Smithgall
金额:
$29.65万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2019-02-28
关键词:
Acquired Immunodeficiency SyndromeAffectAlpha CellAnimal ModelAnti-Retroviral AgentsAutomationBindingBiochemicalBiological AssayBiological Response Modifier TherapyCell surfaceCellsChemicalsChimeric ProteinsCollaborationsCollectionComplementComputer SimulationCrystallizationDataDevelopmentDimerizationDiversity LibraryDockingDown-RegulationFDA approvedFluorescenceFutureGenetic studyGoalsHIVHIV-1ImageImmuneImmunologic SurveillanceIn VitroLeadLibrariesLinkMethodsModelingNIH Program AnnouncementsPathogenesisPharmaceutical PreparationsPopulationProcessPropertyProteinsPublishingRecombinantsReporterResearch PersonnelRoleSeriesSignal TransductionStructureSurface Plasmon ResonanceSystemTherapeuticTherapeutic InterventionTranscriptTranslationsVariantVenusViral PathogenesisVirulence FactorsWorkanalogbasedesigndimerdrug discoveryexperimental studyexpression vectorfluorophorefollow-uphigh throughput screeningin vitro Assayinhibitor/antagonistmutantnef Proteinnovelnovel strategiespeptidomimeticsprotein protein interactionpublic health relevancereceptor downregulationreconstitutionresponsescreeningsmall moleculesmall molecule inhibitorsrc-Family Kinasessuccesstargeted treatmentvalidation studiesvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Nef is an HIV-1 accessory factor essential for viral pathogenesis and immune escape of HIV- infected cells. Many Nef functions require self-association (dimerization), and small molecules that interfere with Nef dimerization may represent a new approach to HIV therapeutics. In this application, which is responsive to PAR-12-058 (Solicitation of Assays for High Throughput Screening to Discover Chemical Probes), we propose to use a cell-based assay for Nef dimerization to discover chemical probes for Nef function that may also represent new antiretroviral drug leads. In this assay, Nef is fused to non-fluorescent, complementary fragments of YFP and co-expressed in the same cell population. Dimerization of Nef results in juxtaposition of the YFP fragments and reconstitution of the fluorophore, a process known as bimolecular fluorescence complementation (BiFC). To simplify the assay for automation, the two Nef-YFP fusion proteins plus an mRFP reporter are expressed from a single vector that drives equivalent translation of all three proteins from a single transcript. Validation studies revealed that Nef-BiFC/mRFP ratios resulting from cells expressing wild-type Nef vs. a dimerization-defective Nef mutant were very clearly separated, with Z-factors consistently in the 0.6-0.7 range. Fully automated pilot screens of ~3,000 compounds identified several active structures that reproducibly blocked Nef dimerization in the low micromolar range. Secondary assays showed that these compounds bind directly to Nef and inhibit its functions related to HIV infectivity and receptor down- regulation. Here we propose to screen a large collection of diverse chemical compounds and evaluate their activity against this critical HIV virulence factor with the following Specific Aims: 1. Screen a large, diverse chemical collection for inhibitors of Nef dimerization using a cell-based BiFC approach. We will implement the Nef-BiFC assay for fully automated screening of 60,000 discrete compounds from two complementary libraries. These include 10,000 non-peptide peptidomimetics from ChemDiv designed to block diverse protein-protein interfaces and 50,000 structures selected from the ChemBridge 410,000 compound core library to maximize structural diversity while enhancing predicted physiochemical properties. 2. Perform follow-up assays to identify the most selective and potent cell-active inhibitors of Nef dimerization, and explore thei mechanism of action. This Aim will identify the most potent and selective chemical probes of HIV-1 Nef function. The first group of assays will determine whether or not each hit compound interacts directly with the Nef protein and impacts its self-association in vitro and in silico, whle the second assay set will explore antiretroviral activity and mechanism in cell-based systems. Successful completion of this project will bring us closer to our long-term goal of discovering cell-active compounds that selectively and potently inhibit as many HIV-1 Nef functions as possible.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10308327
-
项目类别:
-
资助金额:$2.62万
-
财政年份:2021
-
负责人:Thomas E. Smithgall
-
依托单位:
Chemical Biology of HIV-1 Nef
-
批准号:10684695
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2020
-
负责人:Thomas E. Smithgall
-
依托单位:
PROTACS Against Nef as a Functional Cure for HIV Infection
-
批准号:10200007
-
项目类别:
-
资助金额:$29.78万
-
财政年份:2020
-
负责人:Thomas E. Smithgall
-
依托单位:
Chemical Biology of HIV-1 Nef
-
批准号:10471355
-
项目类别:
-
资助金额:$62.75万
-
财政年份:2020
-
负责人:Thomas E. Smithgall
-
依托单位:
Chemical Biology of HIV-1 Nef
-
批准号:10251040
-
项目类别:
-
资助金额:$61.93万
-
财政年份:2020
-
负责人:Thomas E. Smithgall
-
依托单位:
PROTACS Against Nef as a Functional Cure for HIV Infection
-
批准号:10079715
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10687861
-
项目类别:
-
资助金额:$42.69万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10388497
-
项目类别:
-
资助金额:$8.09万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:9814793
-
项目类别:
-
资助金额:$43.56万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10740923
-
项目类别:
-
资助金额:$5.37万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10524124
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10197848
-
项目类别:
-
资助金额:$43.56万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:10434077
-
项目类别:
-
资助金额:$42.69万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
-
批准号:9977987
-
项目类别:
-
资助金额:$43.56万
-
财政年份:2019
-
负责人:Thomas E. Smithgall
-
依托单位:
Validation of the Fes Tyrosine Kinase as an Inhibitor Target in Multiple Myeloma
-
批准号:8879284
-
项目类别:
-
资助金额:$16.75万
-
财政年份:2015
-
负责人:Thomas E. Smithgall
-
依托单位:
Validation of the Fes Tyrosine Kinase as an Inhibitor Target in Multiple Myeloma
-
批准号:9017965
-
项目类别:
-
资助金额:$20.1万
-
财政年份:2015
-
负责人:Thomas E. Smithgall
-
依托单位:
High-throughput Discovery of Chemical Probes for HIV-1 Nef Function
-
批准号:8846220
-
项目类别:
-
资助金额:$29.65万
-
财政年份:2015
-
负责人:Thomas E. Smithgall
-
依托单位:
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
-
批准号:9331725
-
项目类别:
-
资助金额:$99.12万
-
财政年份:2014
-
负责人:Thomas E. Smithgall
-
依托单位:
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS
-
批准号:8790024
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:Thomas E. Smithgall
-
依托单位:
Structural Biology of HIV-1 Nef with Host Effectors and Small Molecule Inhibitors
-
批准号:8629648
-
项目类别:
-
资助金额:$38.41万
-
财政年份:2013
-
负责人:Thomas E. Smithgall
-
依托单位:
海外基金